Colorectal cancer (CRC) risk is modulated by diet and there is convincing evidence of reduced risk with higher non-digestible carbohydrates (NDCs) consumption. Resistant starch (RS), a NDC, positively modulates the expression of oncogenic microRNAs, suggesting that this could be a mechanism through which NDCs protect against CRC. The present study aimed to investigate the effects of supplementation with two NDCs, RS, and polydextrose (PD), on microRNA expression in the macroscopically-normal human rectal epithelium using samples from the DISC Study, a randomized, double-blind, placebo-controlled dietary intervention. We screened 1008 miRNAs in pooled post-intervention rectal mucosal samples from participants allocated to the double placebo group and those supplemented with both RS and PD. A total of 111 miRNAs were up-or down-regulated by at least twofold in the RS + PD group compared with the control group. From these, eight were selected for quantification in individual participant samples by qPCR, and fold-change direction was consistent with the array for seven miRNAs. The inconsistency for miR-133b and the lower fold-change values observed for the seven miRNAs is probably because qPCR of individual participant samples is a more robust and sensitive method of quantification than the array. miR-32 expression was increased by approximately threefold (P = 0.033) in the rectal mucosa of participants supplemented with RS + PD compared with placebo. miR-32 is involved in the regulation of processes such as cell proliferation that are dysregulated in CRC. Furthermore, miR-32 may affect non-canonical NF-κB signaling via regulation of TRAF3 expression and consequently NIK stabilization.
the large bowel to produce the short-chain fatty acids (SCFAs) butyrate (the preferred energy source for colonocytes), propionate and acetate.
Butyrate, produced primarily by bacterial species of the Clostridia, Roseburia, and Eubacteria genera, 3 has chemoprotective anti-inflammatory and anti-proliferative properties and regulates apoptosis in both normal and cancerous cells. 4, 5 Butyrate has effects on epigenetic mechanisms that regulate gene expression and are important in colorectal tumorigenesis, including its role as a histone deacetylase inhibitor (HDACi) 6 and effects on microRNA (miRNA) expression. 7, 8 miRNAs are small, non-coding RNAs that regulate the expression of their target genes at a post-transcriptional level by degrading messenger RNA or blocking translation. Over 1500 miRNAs have been identified in humans and have been predicted to regulate the expression of up to 60% of genes, 9, 10 consequently regulating multiple biological processes including cell proliferation, differentiation, and apoptosis. Abnormal miRNA expression is observed in colorectal tissue as well as plasma, urine, and stool samples from CRC patients. 11, 12 miRNA expression is modulated by multiple dietary factors; for example the expression of 250, 198, and 99 miRNAs was associated with intakes of carbohydrate, sucrose, and wholegrains, respectively, and some of these miRNAs showed differential expression between normal and tumor tissue. 13 A limited number of studies have 14 Follow-up analysis by qPCR showed that butyrate treatment reduced expression of miRNAs belonging to the oncogenic miR-17-92 cluster and decreased cell proliferation. Hu et al also reported that butyrate exposure altered expression of 44 miRNAs in HCT-116 cells, 18 of which were confirmed by qPCR. 7 Humphreys et al were the first to investigate the effects of RS and butyrate on expression of miR-17-92 cluster members in a human intervention study. 15 Supplementation of a high red meat diet, which increased miR-17-92 expression by approximately 30%, with butyrylated RS for 4 wk restored expression to baseline levels, suggesting that RS reversed the detrimental effects of red meat on expression of oncogenic miRNAs.
In the current study, we hypothesised that NDCs are protective against CRC by regulating the expression of miRNAs, in particular by down-regulating expression of miRNAs that are upregulated in CRC. For the first time, we used a whole miRNome PCR array to screen for candidate miRNAs that are differentially expressed in the macroscopically-normal rectal mucosa of healthy participants following supplementation with two NDCs (RS and PD). We validated the findings from the miRNome array for eight miRNAs by qPCR using RNA samples from 29 individual participants. 
| Intervention methodology
The samples utilized for the present study were collected as part of the DISC Study, a double-blind, randomized, placebo-controlled dietary intervention that supplemented healthy participants with RS and/or PD for 50 d in a 2 × 2 factorial design. 16 For the purpose of this study, the following two groups of participants were used: 
| Study design
We designed a two-phase study to identify miRNAs modulated by
NDCs (see Fig. 1 ). In the screening phase, we pooled equivalent for homogenization by centrifugation for 2 m at maximum speed.
RNA was eluted in 30 µL of RNase-free water. Concentration and RNA purity were determined using the NanoDrop 1000 spectrophotometer (Thermo Scientific) and NanoDrop 1000
Software version 3.7.1. RNA integrity was assessed by agarose gel electrophoresis.
| Synthesis of cDNA
cDNA was synthesized from 0.8 μg of RNA using the miScript II RT Kit (Qiagen) as described by the manufacturer. The miScript HiSpec Buffer (5×) was used during reverse transcription to enable subsequent quantification of mature miRNAs. The samples were incubated for 60 m at 37°C followed by 5 m at 95°C using the Sensoquest lab cycler (Göttingen, Germany).
| miRNome array
Prior to analyses, cDNA samples were diluted ten times. Expression of 1008 miRNAs plus six quality controls and six reference RNAs were quantified by qPCR using the 96 well plate Human miRNome miScript® miRNA PCR array (Qiagen) as described by the manufacturer (see Fig. 1 ). miRNAs with Ct values over 35 were classed as undetected. Raw data were normalized against the six reference RNAs and, as subsequent validation of miRNA expression by qPCR was normalized against only two reference RNAs, also against the selected two reference RNAs (RNU-6 and SNORD68) to check that these data were comparable with both normalization methods. Technical performance of the plates was checked using the integrated quality controls included on all the array plates.
| Validation of miRNA expression by quantitative PCR
Quantification of the eight selected miRNAs for validation and two reference RNAs (SNORD68 and RNU-6) in individual samples was performed by qPCR using the Applied Biosystems® StepOnePlus™ system, the miScript SYBR Green PCR Kit and custom miScript primer assays (Qiagen, UK) as described by the manufacturer.
Prior to analysis of the qPCR data, the melt curves were checked for a single peak and a constant threshold value was set for each miRNA separately for all of the samples by taking the average of the set thresholds for each miRNA for every plate. Ct values greater than 35 were classed as undetected and raw data were normalized relative to the geometric mean of RNU-6 and SNORD68.
| Statistical analyses
The data, expressed as adjusted relative copies (2 −ΔCt × 1000, relative to the geometric mean of SNORD68 and RNU-6), were analyzed using Minitab® v.17. Prior to analyses, data were checked for a normal distribution using the Kolmogorov-Smirnov test. Data that were not normally-distributed were transformed appropriately, using log 10 or by taking the square root.
Differences between the two treatment groups were analyzed using the ANOVA General Linear Model (GLM), adjusting for preintervention expression, age, gender, endoscopy procedure, smoking status, and BMI as covariates. 
| Participant characteristics
Samples from a total of 29 participants were utilized for this study, comprising 15 Control participants and 14 Double Intervention participants. Participant characteristics are summarized in Table 1 .
Mean age of participants in both groups was similar (49 and 51 years for Control and RS + PD, respectively), with the youngest participant being aged 30 and oldest aged 74. With the exception of one Control participant, all participants were Caucasian. In both groups, colonoscopy was the main endoscopy procedure at baseline.
The participants were well-matched for BMI (most were overweight or obese) and smoking behavior (73% and 71% were never or former smokers for Control and RS + PD groups, respectively). The observed similarity in participant characteristics is evidence of the success of the randomization process. Fig. 2A) .
A 
| Normalization of PCR array data
Raw data were normalized relative to all six reference RNAs included on the array plates and to the two selected reference RNAs (RNU-6
and SNORD68) used during the validation stage of the study. We checked that both normalization methods were comparable for all 111 miRNAs showing a fold-change ≥ 2 (Fig. 2B) . From the 1008 miRNAs for which there were probes on the array, 69 miRNAs showed ≥2-fold difference in expression when normalized relative to only RNU-6 and SNORD-68 compared with 111 for normalization to all six reference RNAs. In all cases where the normalization methods resulted in different fold-change results, fold-changes were very small (between −1.13 and 1.12) and the difference in foldchange between the two normalization methods did not exceed 0.14. miR-3156-5p, miR-637, and miR-600 were excluded at this stage, leaving five miRNAs up-regulated ≥2-fold (Fig. 2C ) and 21 downregulated ≥2-fold (Fig. 2D) .
| Selection of miRNAs for individual participant analysis
From the remaining 26 miRNAs, the top three miRNAs showing the greatest fold up-regulation and the top four miRNAs showing the greatest fold down-regulation were selected for further investigation.
These were: miR-135a-5p, miR-517-5p, and miR-26a-1-3p (upregulated genes) and miR-133b, miR-640, miR-1287-5p, and miR-127-3p
(down-regulated genes). In addition, miR-32 was selected due to its role in colorectal carcinogenesis. Table 2 ). There were no statistically significant differences in the expression of miR-26a, miR-127, miR-133b, miR-135a, miR-517, miR-640, or miR-1287 between the Control and RS + PD groups.
| Comparison of PCR array and qPCR of individual participant data
Quantification of the eight selected miRNAs in individual samples allowed for comparison with the originally obtained PCR array data.
For the PCR array data, fold-change was calculated for each miRNA by dividing the relative copies (2
−ΔCt
) for the pooled RS + PD group sample by that for the pooled Control group sample. For the individual Data are expressed as adjusted copies. Data are presented as least square means (LSMs) and 95% confidence intervals (CIs) are included in parentheses. *P < 0.05 (ANOVA GLM).
participant analysis stage, the means of the relative copies for each treatment group were calculated and from this the fold-change was estimated. The resulting data are summarized in Table 3 . The direction of fold-change were the same for seven out of eight miRNAs, the exception being miR-133b, and we observed some differences in the degree of change, for example the magnitude of fold-change in miR-135a for individual participant data was half that observed in the screening array (1.49 vs 3.19).
| DISCUSSION
miRNAs regulate the expression of thousands of genes by inhibiting their expression and, consequently, have effects on many biological processes including those involved in tumorigenesis. 7, 15, 18 Abnormal expression of miRNAs is implicated in the pathogenesis of CRC, where it is associated with disease progression, treatment response, and prognosis. 19, 20 miRNAs have potential to be used as cancer biomarkers since altered expression is observed not only in colorectal tissue but also in the plasma, stool, and urine from CRC patients. 11, 12 However, little is known about the potential of miRNAs as early markers of CRC risk and how dietary factors may modulate these markers.
In the current study, we used a multi-step approach to identify miRNAs in the colorectal mucosa of healthy individuals that are potentially regulated by two NDCs (RS and PD). Using a whole miRNome PCR array screen, we first compared the expression of 1008 miRNAs in pooled samples from rectal mucosal biopsies from participants who were randomized to RS + PD or to Control for 50 d.
The use of pooling techniques has been applied widely in "omics" studies including those analyzing miRNA expression [21] [22] [23] and is particularly valuable when samples are precious or limited. 24 This screening stage and invasion in colorectal and gastric cancer cells and reduces apoptosis. 17, 26, 27 There also appears to be a connection between miR-32 and inflammation via the regulation of tumor necrosis factor receptor-associated factor-3 (TRAF3), an activator of the noncanonical NF-κB pathway. 28 Therefore, downregulation of TRAF3
by miR-32 could lead to increased inflammation and effects on other processes such as cell proliferation and cell death through stimulated NF-κB signaling. [29] [30] [31] While our findings are contradictory to evidence supporting butyrate's anti-inflammatory properties, it is possible that effects on miR-32 expression and consequently on the NF-κB non-canonical pathway could be one of the mechanisms via which NDCs modulate processes such as cell proliferation and apoptosis. 5 The very limited research on the effects of NDCs on miRNA expression in the large bowel mucosa suggests that RS and butyrate may reduce the expression of oncogenic miRNAs. 14, 15 To our knowledge, our study is the first to report the effects of NDC supplementation on miR-32 expression in the human colorectal epithelium. The observed increase in miR-32 expression could be one of the mechanisms through which, in healthy colorectal cells, butyrate stimulates cell proliferation. [32] [33] [34] In contrast, NDCs and butyrate reduce cell proliferation and promote apoptosis in CRC cells, [35] [36] [37] [38] [39] referred to as the butyrate paradox, 40 and the role of miRNAs in mediating these phenomena in both healthy and cancer tissue deserves further investigation. 
